Quality control and safety assessment of BCG vaccines in the post-genomic era

Tzvetelina Stefanova, Tzvetelina Stefanova

Abstract

A hundred and five years ago, Albert Calmette and Camille Guérin began a daunting task, which is unmatched even today, that led to the most widely used vaccine in human history. Despite a century of scientific advances, BCG (an acronym for Bacillus Calmette-Guérin) remains the only vaccine for prevention of tuberculosis. Due to the fact that the use of BCG vaccines will continue, either as a stand-alone or as a prime vaccine in prime-boost immunization strategies, the World Health Organization (WHO) has underlined the necessity for further work toward better characterization, evaluation and quality control of the BCG vaccine, taking into account recent advances in genetics and molecular biology. The potential benefit of such improved characterization could be addressed to better and easier differentiation between sub-strains used by different manufacturers. It may help to ensure consistency of production in terms of genetic stability and it may also help the clinical evaluation of new antituberculosis vaccines. Last but not least, the state-of-the-art technologies could facilitate the quality control performed by the manufacturers and by National Control Authorities as well.

Keywords: BCG vaccine; genomic characterization; quality control methods.

References

    1. World Health Organization. Vaccine-preventable diseases: monitoring system 2013 global summary [Internet]. Geneva (Switzerland): World Health Organization; c2013. WHO-UNICEF Estimates of BCG Coverage. 2013 Jul 14 [cited 2014 May 20]; [about 3 screens]. Available from: .
    1. Ho MM. Corbel MJ. Knezevic I. Roumiantzeff M. Vaccine. Vol. 23. Geneva (Switzerland): WHO; 2004. 2005. Report on a WHO consultation on the characterisation of BCG vaccines; pp. 5700–5704.
    1. Knezevic I, Corbel MJ. WHO discussion on the improvement of the quality control of BCG vaccines. Pasteur Institute, Paris, France, 7 June 2005. Vaccine.
    1. Knezevic I. Corbel MJ. Vaccine. Vol. 24. Paris (France): Pasteur Institute; 2006. WHO discussion on the improvement of the quality control of BCG vaccines; pp. 3874–3877. 2005.
    1. World Health Organization . Expert committee on biological standardization. Requirements for dried BCG vaccine. 1987. pp. 60–92. WHO Technical Report Series No. 745.
    1. European Pharmacopoea . . Strasbourg: 2008. Directorate for the quality of medicines of the council of Europe (EDQM). BCG vaccine, freeze-dried; pp. 759–761.
    1. Orme IM. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect Immun. 1988;56:3310–3312.
    1. Parra M. Lim YA. Kolibab K. Derrick S. Cadieux N. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis . Clin Vaccine Immun. 2009;16:1025–1032.
    1. Ho MM. Markey K. Rigsby P. Jensen SE. Gairola S. Seki M. Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine. 2008;26:4754–4757.
    1. Jensen SE. Hubrechts P. Klein B. Haslov KR. Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccine. Biologicals. 2008;36:308–314.
    1. Crispen RG. Rapid testing of freeze dried BCG vaccine for stability and viability. Symp Ser Immunobiol Stand. 1971;17:205–210.
    1. Lundin A. Use of firefly luciferase in ATP related assays of biomass, enzymes and metabolites. Methods Enzymol. 2000;305:346–370.
    1. Allen RC. In: Bioluminescence and chemiluminescence. DeLuca M, editor; McElroy WD, editor. New York (NY): Academic Press; 1981. pp. 63–73.
    1. Askgaard DS. Gottschau A. Knudsen K. Bennedsen J. Firefly luciferase assay of adenosine triphosphate as a tool of quantitation of the viability of BCG vaccines. Biologicals. 1995;23:55–60.
    1. World Health Organization. Geneva (Switzerland): Expert committee on biological standardization. In: Recommendations to assure the quality, safety and efficacy of BCG vaccines. 2011. p.1–48.
    1. Meeting report: WHO Informal Consultation on Standardization and Evaluation of BCG Vaccines 2009; Geneva (Switzerland): [cited 2014 May 20]. Available from:
    1. Cole ST. Brosch R. Parkhill J. Garnier T. Churcher C. Harris D. Gordon SV. Eiglmeier K. Gas S. Barry CE., 3rd Tekaia F. Badcock K. Basham D. Brown D. Chillingworth T. Connor R. Davies R. Devlin K. Feltwell T. Gentles S. Hamlin N. Holroyd S. Hornsby T. Jagels K. Krogh A. McLean J. Moule S. Murphy L. Oliver K. Osborne J. Quail MA. Rajandream MA. Rogers J. Rutter S. Seeger K. Skelton J. Squares R. Squares S. Sulston JE. Taylor K. Whitehead S. Barrell BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393:537–544.
    1. Behr MA. Wilson MA. Gill WP. Salamon H. Schoolnik GK. Rane S. Small PM. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999;284:1520–1523.
    1. Bedwell J. Kairo SK. Behr MA. Bygraves JA. Identification of substrains of BCG vaccine using multiplex PCR. Vaccine. 2001;19:2146–2151.
    1. Markey K. Ho MM. Choudhury B. Seki M. Ju L. Castello-Branco LR. Gairola S. Zhao A. Shibayama K. Andre M. Corbel MJ. Report of an international collaborative study to evaluate the suitability of multiplex PCR as an identity assay for different sub-strains of BCG vaccine. Vaccine. 2010;28(43):6964–6969.
    1. Castillo-Rodal AI. Castanon-Arreola M. Hernandez-Pando R. Calva JJ. Sada-Diaz E. Lopez-Vidal Y. BCG sub strains confers different protection against Mycobacterium tuberculosis infection in BALB/c model of progressive pulmonary tuberculosis. Infect Immun. 2006;74:1718–1724.
    1. Brosch R. Gordon SV. Garnier T. Eiglmeier K. Frigui W. Valenti P. Dos Santos S. Duthoy S. Lacroix C. Garcia-Pelayo C. Inwald JK. Golby P. Garcia JN. Hewinson RG. Behr MA. Quail MA. Churcher C. Barrell BG. Parkhill J. Cole ST. Genome plasticity of BCG and impact on vaccine efficacy . 2007;104:5596–5601.
    1. Stefanova T. Chouchkova M. Hinds J. Butcher P. Inwald J. Dale J. Genetic composition of Mycobacterium bovis BCG substrain Sofia. J Clin Microbiol. 2003;41:5349.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever